- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | - / - |
| Spread | - |
| Schluss Vortag | - |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief - Tageshoch - | |
| Marktkapitalisierung | 1,85 Mio. € |
| Aktienanzahl | 42,59 Mio. |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
Merger mit Biosight
-Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
-Combined Company Will be Well-Funded with Cash Position of approx.$50 Million Expected at Closing
-Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months
https://www.advaxis.com/news-releases/news-release-details/advaxis-and-biosight-announce-entry-definitive-merger-agreement